Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
09/16/2019 09/17/2019 09/18/2019 09/19/2019 09/20/2019 Date
8.18(c) 8.28(c) 7.97(c) 7.58(c) 7.63(c) Last
222 133 146 333 250 727 315 428 94 042 Volume
+2.12% +1.22% -3.74% -4.89% +0.66% Change
More quotes
Financials (EUR)
Sales 2019 40,0 M
EBIT 2019 -17,5 M
Net income 2019 -15,1 M
Finance 2019 33,4 M
Yield 2019 -
Sales 2020 25,4 M
EBIT 2020 -34,8 M
Net income 2020 -35,2 M
Finance 2020 20,0 M
Yield 2020 -
P/E ratio 2019 -12,9x
P/E ratio 2020 -5,46x
EV / Sales2019 4,10x
EV / Sales2020 6,98x
Capitalization 197 M
More Financials
Company
Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes. At the end of 2017, the group had a portfolio of 2 products in clinical development, including 1 in Phase II (Imeglimin for the treatment of... 
More about the company
Surperformance© ratings of Poxel
Trading Rating : Investor Rating :
More Ratings
Latest news on POXEL
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate..
AQ
08/06POXEL : Initiates Pharmacokinetic Pharmacodynamic Study as part of the Phase 2a ..
AQ
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
06/26Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results..
AQ
06/25POXEL : and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results ..
PU
04/10Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Im..
AQ
04/08POXEL : Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Tr..
PU
04/03POXEL SA : quaterly sales release
01/29POXEL : Announces its Financial Calendar for 2019
PU
2018Poxel Announces Third Quarter and Nine Months 2018 Financial Update
AQ
More news
Analyst Recommendations on POXEL
More recommendations
Sector news : Bio Therapeutic Drugs
09/20Brazil Announces Criminal Charges Against 7 Vale Employees in Dam Collapse--U..
DJ
09/20REGENERON PHARMACEUTICALS : Sanofi Get Positive CHMP Opinion for Dupixent
DJ
09/19Animal health sector aims to emulate Zoetis biotech leap
RE
09/18BIOGEN : to Study Higher Dose of Spinraza in Spinal Muscular Atrophy
DJ
09/16A Plan to Fight Hep C -- WSJ
DJ
More sector news : Bio Therapeutic Drugs
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 15,13  €
Last Close Price 7,63  €
Spread / Highest target 123%
Spread / Average Target 98,3%
Spread / Lowest Target 79,6%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Anne Renevot Chief Financial Officer
Sophie Hallakou-Bozec Senior Vice Chairman-Research & Development
Christophe Arbet-Engels Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
POXEL49.90%217
GILEAD SCIENCES6.19%83 535
VERTEX PHARMACEUTICALS7.49%45 274
REGENERON PHARMACEUTICALS-20.78%31 311
GENMAB29.51%13 297
NEUROCRINE BIOSCIENCES, INC.41.20%9 295